Bispecific antibody market seen topping $53 billion by 2030

The Business Research Company projects the global bispecific monoclonal antibodies market will reach more than $53 billion by 2030, driven by cancer and autoimmune disease demand, antibody engineering advances and expanding regulatory approvals. North America is expected to lead the market, while Hemlibra is forecast to remain the largest drug segment.

Why it matters: - The forecast points to a fast-growing niche inside oncology drugs and broader pharmaceuticals. - Bispecific monoclonal antibodies are projected to account for about 12% of the oncology drugs parent market by 2030, based on the report’s estimates. - The market is also expected to represent nearly 2% of the total pharmaceuticals market value by 2030.

What happened: - The Business Research Company released its Bi-Specific MAbS Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report estimates the bispecific monoclonal antibodies market will surpass $53 billion in 2030. - The report puts the market’s compound annual growth rate at 15% leading up to 2030. - North America is forecast to be the largest region in 2030, with a market value of $28 billion. - The USA is projected to be the largest country in 2030, valued at $25 billion. - Hemlibra is forecast to be the largest drug segment in 2030, accounting for 75% of the market, or about $40 billion. - The market is segmented by drug into BLINCYTO, Hemlibra and other drugs. - The market is segmented by indication into cancer, hemophilia, retinal disorders, autoimmune diseases and other indications. - The market is segmented by end user into hospitals, specialty clinics, academic and research institutes and ambulatory care centers. - A free sample request and the full report are available through the company’s sample request page and the detailed market report.

The details: - North America is expected to grow from $17 billion in 2025 to $28 billion in 2030, a 10% CAGR. - The report links North American growth to adoption of targeted immunotherapies, clinical success across oncology indications, biopharmaceutical research capabilities, investment in next-generation biologics, biotechnology-pharmaceutical partnerships and favorable regulatory pathways. - The USA is expected to grow from $16 billion in 2025 to $25 billion in 2030, also at a 10% CAGR. - The report ties U.S. growth to cancer and hematological disorder prevalence, biologics manufacturing capacity, precision medicine adoption, clinical trial activity, healthcare spending on advanced biologics and pipeline expansion by leading drugmakers. - The hemlibra segment is supported by rising hemophilia diagnosis, prophylactic treatment adoption, efficacy in reducing bleeding episodes, physician preference for long-acting biologics, earlier disease management and improved adherence. - The report says the biggest growth opportunities are in BLINCYTO, Hemlibra and other drugs, which together are projected to add more than $26 billion by 2030. - The BLINCYTO market is projected to grow by $2 billion from 2025 to 2030. - The Hemlibra market is projected to grow by $18 billion over the same period. - The other drugs segment is projected to grow by $6 billion over the same period. - The report says rising cancer and autoimmune disease prevalence should add about 3.0% annual growth to the market. - Technological advances in antibody engineering are projected to contribute around 2.5% annual growth. - Increasing regulatory approvals and an expanding pipeline are projected to contribute about 1.8% annual growth. - The report says advances in antibody discovery platforms, molecular design and protein engineering are improving stability, specificity, manufacturing and performance. - The report says broader regulatory acceptance and late-stage development investment are expanding commercialization opportunities. - The Business Research Company says its 2026 market reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The company says it has published more than 30,000 reports across 27 industries and 60 geographies, with research powered by 1,500,000 datasets, secondary research and interviews with industry leaders.

Between the lines: - The forecast suggests bispecific antibodies are moving from a specialized treatment class into a larger commercial category with strong geographic concentration in the U.S. and North America. - The hemlibra concentration implies the market remains heavily dependent on a small number of products rather than broad drug diversity. - The growth drivers point to a market being shaped by clinical demand, better engineering and a clearer regulatory path, not just by pricing or volume alone.

What's next: - The report expects continued expansion through 2030 as more bispecific therapies move through development and commercialization. - Further growth will likely depend on new approvals, broader clinical use and sustained investment in manufacturing and antibody engineering. - The company says its broader report package is designed to support market-entry, competitor-tracking and supplier-distributor research.